Probing single-cell biology ex vivo for personalized systems medicine

Thumbnail

Event details

Date 18.04.2023
Hour 11:0012:00
Speaker Berend Snijder
Assistant Professor of Molecular Systems Biology at the ETH Zurich
Location Online
Category Conferences - Seminars
Event Language English
Abstract: 
The cellular and molecular systems that determine drug responses in cancer are complex, highly individual, and incompletely understood. As a result, identifying effective treatments for individual patients is still often challenging, particularly in relapsed disease. To tackle this challenge, we are developing Pharmacoscopy, which allows the measurement of hundreds of ex vivo drug responses in small patient biopsies by immunofluorescence, automated confocal microscopy, single-cell image analysis, and machine learning. In this talk, I will show: 1) Results from interventional clinical trials showing that Pharmacoscopy identifies effective treatments; 2) How we can use deep learning and spatial analyses to discover new cancer and immune cell phenotypes; And 3) how, when combined with patient-centric multi-OMIC measurements and matched patient data, Pharmacoscopy enables the identification of the molecular and cellular systems that govern treatment response individuality.
 
a “pharmacoscopy” method figure
© 2023 EPFL

Bio:
Berend Snijder is an Assistant Professor of Molecular Systems Biology at the ETH Zurich in Switzerland, as well as a group leader at the Swiss Institute of Bioinformatics and the Comprehensive Cancer Center Zurich, with funding support from the Swiss National Science Foundation, an ERC Starting Grant, and public/private partnerships with pharmaceutical companies, among others. Berend received his MSc degree in Biomedical Sciences with honors from the University of Amsterdam and performed his Ph.D. studies working on image-based screening and cell-to-cell variability analyses in the lab of Lucas Pelkmans at the IMSB, ETH Zurich, for which he was awarded the ETH Medal. For his postdoctoral studies, he joined the lab of Giulio Superti-Furga at the Center for Molecular Medicine in Vienna, where he received a Young Investigator Award from the Austrian Society for Hematology and Medical Oncology, and co-founded the biotech Allcyte GmbH, acquired in 2021. The Snijder lab is pioneering Pharmacoscopy, a method to measure ex vivo drug responses in patient biopsies using automated microscopy, image analysis, and deep learning to improve treatment selection in cancer and gain systems-level insights into why patients respond differently to medications. Please see https://snijderlab.org for more information.
 

Practical information

  • General public
  • Free
  • This event is internal

Organizer

Contact

Event broadcasted in

Share